Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antiplatelet drugs are a class of medications that prevent platelet aggregation and blood clot formation, primarily used to prevent cardiovascular events such as heart attacks and strokes. They target various molecules involved in platelet activation, including enzymes like cyclooxygenase and receptors like P2Y12 and Glycoprotein IIb/IIIa.
Inhibition of cyclooxygenase (COX-1) by aspirin, blockade of ADP receptors (P2Y12) by clopidogrel and prasugrel, inhibition of phosphodiesterase by dipyridamole, blockade of Glycoprotein IIb/IIIa receptors by abciximab and tirofiban
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antiplatelet action (Not applicable).